Published in Thyroid on July 01, 2008
Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol (2012) 1.36
Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol (2010) 1.14
Galectins as cancer biomarkers. Cancers (Basel) (2010) 1.08
Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget (2013) 1.05
Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer (2009) 0.99
Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med (2014) 0.92
Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis (2011) 0.91
Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples. Biomark Cancer (2010) 0.91
Soluble IgE receptors--elements of the IgE network. Immunol Lett (2011) 0.89
The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers (Basel) (2010) 0.88
Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci Rep (2015) 0.86
Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm Res (2009) 0.85
Serum biomarkers of papillary thyroid cancer. J Otolaryngol Head Neck Surg (2013) 0.83
Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J (2012) 0.83
Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol (2010) 0.82
B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. Oncotarget (2015) 0.79
Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation. J Am Heart Assoc (2016) 0.78
Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol (2014) 0.78
Biomarkers of metastatic potential in cultured adenocarcinoma clones. Clin Exp Metastasis (2010) 0.77
Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol (2017) 0.77
Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles. Aging (Albany NY) (2016) 0.76
Serum Galectin-3: diagnostic value for papillary thyroid carcinoma. Ulus Cerrahi Derg (2015) 0.75
Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis. Can J Surg (2012) 0.75
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett (2017) 0.75
Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1. Med Oncol (2017) 0.75
Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2007) 4.66
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope (2011) 2.55
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39
Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem (2003) 2.27
The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab (2008) 2.06
Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care (2009) 2.06
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol (2008) 1.94
Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab (2008) 1.91
Chemical biology of the sugar code. Chembiochem (2004) 1.78
Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 1.68
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene (2005) 1.64
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol (2009) 1.64
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol (2002) 1.60
Thyroid autoimmunity and hypothyroidism before and during pregnancy. Hum Reprod Update (2003) 1.57
Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol (2004) 1.57
GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med (2010) 1.57
What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54
Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem (2002) 1.53
Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A (2008) 1.52
An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol (2007) 1.47
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47
Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology (2009) 1.47
From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci (2011) 1.46
Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells. J Cell Biol (2005) 1.43
Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res (2004) 1.42
SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma (2012) 1.39
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res (2004) 1.38
Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37
Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res (2004) 1.36
Thyroid disease and female reproduction. Clin Endocrinol (Oxf) (2007) 1.35
Epithelial-mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cells. PLoS One (2009) 1.32
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. Biochemistry (2005) 1.29
Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood (2009) 1.27
The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc. Proc Natl Acad Sci U S A (2005) 1.26
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood (2009) 1.24
Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol (2004) 1.23
Non-traumatic myositis ossificans in the paraspinal muscles. Eur Arch Otorhinolaryngol (2005) 1.22
TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet (2011) 1.20
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19
MicroRNA-7a regulates pancreatic β cell function. J Clin Invest (2014) 1.18
Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab (2004) 1.15
Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 1.15
The sugar code: functional lectinomics. Biochim Biophys Acta (2002) 1.14
Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol (2002) 1.14
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood (2004) 1.14
Quaternary solution structures of galectins-1, -3, and -7. Glycobiology (2003) 1.13
UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem (2005) 1.13
Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol (2009) 1.13
Rituximab inhibits B-cell receptor signaling. Blood (2009) 1.13
The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11
Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab (2003) 1.11
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J (2004) 1.11
Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans. J Clin Invest (2010) 1.09
Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem (2006) 1.09
PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood (2007) 1.06
Photoderivatized polymer thin films at quartz crystal microbalance surfaces: sensors for carbohydrate-protein interactions. Anal Chem (2007) 1.05
Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene (2003) 1.05
Galectin-4-regulated delivery of glycoproteins to the brush border membrane of enterocyte-like cells. Traffic (2009) 1.05
Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol (2003) 1.05
Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes (2011) 1.05
Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood (2005) 1.05
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood (2013) 1.04
Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer (2003) 1.04
Atypical adenomatous hyperplasia of lung: its incidence and analysis of clinical, glycohistochemical and structural features including newly defined growth regulators and vascularization. Lung Cancer (2003) 1.04
Glycosyldisulfides from dynamic combinatorial libraries as O-glycoside mimetics for plant and endogenous lectins: their reactivities in solid-phase and cell assays and conformational analysis by molecular dynamics simulations. Bioorg Med Chem (2006) 1.03
Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology (2005) 1.03
Unique conformer selection of human growth-regulatory lectin galectin-1 for ganglioside GM1 versus bacterial toxins. Biochemistry (2003) 1.02
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat (2007) 1.02
Micrometastases in thyroid cancer. An important finding? Surg Oncol (2008) 1.02
Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. Oncogene (2004) 1.02
Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res (2001) 1.01
From structural to functional glycomics: core substitutions as molecular switches for shape and lectin affinity of N-glycans. Biol Chem (2009) 1.01
Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab (2012) 1.01